Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06352788 · ClinicalTrials.gov registry record · NA
From Opinion to Evidence: Multi-site Evaluation of Custom Dynamic Orthosis Best Practices
A NA study of Foot Injury, sponsored by Jason Wilken.
- Recruiting
- Registry status
- NA
- Development phase
- 35
- Enrollment target
- 5
- Study locations
NCT06352788: Recruiting NA study of Foot Injury, sponsored by Jason Wilken.
NCT06352788 is a NA study of Foot Injury that is actively recruiting participants, run by Jason Wilken. The registered enrollment target is 35 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06352788, a NA study of Foot Injury, is actively recruiting participants, sponsored by Jason Wilken.
- RECRUITING
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is designed to support evidence-based practice and optimal care by evaluating how different configurations of two types of carbon fiber custom dynamic orthoses (CDOs) influences outcomes following traumatic lower extremity injury.
Primary Outcome
The Patient Reported Outcome Information System (PROMIS) Physical Function Computer Adaptive Test (CAT) is a computerized assessment measuring physical function. It is scored using a T-score in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. In a given PROMIS domain, a T-score above 50 represents greater physical function than the population average. Larger scores are better.
Conditions Studied
Interventions
- DEVICE Modular Carbon Fiber Custom Dynamic Orthosis (CDO)
- DEVICE Mono Carbon Fiber Custom Dynamic Orthosis (CDO)
Study Locations (5)
Minnesota
- Minneapolis VA Health Care System - Motion Analysis Laboratory - Minneapolis
- Mayo Clinic - Motion Analysis Lab - Rochester
California
- Naval Medical Center San Diego - Clinical Biomechanics Laboratory - San Diego
Iowa
- University of Iowa - Iowa City
Tennessee
- Vanderbilt University - Zelik Lab For Biomechanics & Assistive Technology - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2024-07-02 |
| Est. Completion | 2028-09-01 |
| Phase | NA |
What NCT06352788 shows while recruiting
NCT06352788 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Foot Injury appearing as the primary indexed condition, and to 2 interventions - of which Modular Carbon Fiber Custom Dynamic Orthosis (CDO) is the first listed.
NCT06352788 lists 5 locations in 4 states (Minnesota, California, Iowa).
Frequently Asked Questions
What is clinical trial NCT06352788 about?
NCT06352788 is a clinical study titled "From Opinion to Evidence: Multi-site Evaluation of Custom Dynamic Orthosis Best Practices". This study is designed to support evidence-based practice and optimal care by evaluating how different configurations of two types of carbon fiber custom dynamic orthoses (CDOs) influences outcomes following traumatic lower extremity injury.
What is the current status of trial NCT06352788?
This trial is currently recruiting. It is a NA study. The enrollment target is 35 participants. The study started on 2024-07-02. Estimated completion is 2028-09-01.
What conditions does trial NCT06352788 study?
This clinical trial studies the following conditions: Foot Injury.
What interventions are being tested in trial NCT06352788?
The interventions under investigation include: Modular Carbon Fiber Custom Dynamic Orthosis (CDO) (DEVICE), Mono Carbon Fiber Custom Dynamic Orthosis (CDO) (DEVICE).
Who is sponsoring clinical trial NCT06352788?
This trial is sponsored by Jason Wilken, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06352788 being conducted?
This trial has 5 study locations across California, Iowa, Minnesota, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Foot Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06352788's enrollment target sits among peer trials
35 1565th of 2000 higher than 431 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI